Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed specialty pharmaceutical company with a long heritage dating back to 1845 (when it was known as FH Faulding & Co). The Company has built its success on the development and manufacture of branded and generic products distributed both locally and overseas.

Many of those products are made in its 12,000m2 facility located in Salisbury, South Australia (including Astrix, Magnoplasm and Percutane). This is an established GMP manufacturing facility (as accredited by various regulatory bodies including FDA, TGA & MHRA) and capable of developing products from formulation stage, right through to commercial scale manufacture.

The drug development and manufacturing operations are supported by approximately 180 staff with more than 20 formulation and analytical scientists dedicated to the development of new products. One of the newest products to be developed and manufactured at the Salisbury facility is Magnoplasm Splintex.